However, a systemic supply of estrogen can provide undesirable side effects, for example, a high risk of systemic thrombosis, tumor development, etc. The creation of an estrogen receptor agonist, which could be specific to cone cells, but without systemic adverse events, could be an interesting approach. This evidence concerns the gene ESR1 and neoplasm.